PSNL

AI MemoPost-earnings T+3

Personalis

As of 2026-08-14/Post-earnings T+3/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-14 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

high

Horizon

—

Key catalyst

Q2 clinical and reimbursement acceleration • 2026-08-04

Base target: $15 / p=40% prob

Biggest risk

The deal creates a closing and consideration risk, while Personalis remains loss-making and has limited analyst coverage. Population-sequencing revenue declined 9% year over year, and no reliable post-print analyst revision set is available in the packet.

Invalidation

Break below $12 or thesis failure.

What would change my mind?

The Q2 print supports a strengthening commercial trajectory: clinical volume, clinical revenue, Medicare coverage, and physician adoption all improved materially. The Tempus transaction also provides a potential near-term value reference at $16.25 per share.

Research note

Recommendation

—

Confidence

high

As of

2026-08-14

Base target

$15

p=40%

Bull target

$16

p=45%

Bear target

$12

p=15%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

MRD adoption and further reimbursement expansion
The Q2 print supports a strengthening commercial trajectory: clinical volume, clinical revenue, Medicare coverage, and physician adoption all improved materially.
The Tempus transaction also provides a potential near-term value reference at $16.25 per share.

BearKey bullets

Clinical growth depends on reimbursement expansion, physician adoption, and continued evidence generation.
Insider Form 4 activity included open-market sales by senior officers; this is a sentiment and alignment risk, not evidence of operating deterioration.
[#SEC-FORM4-2026-07-15] [#SEC-FORM4-2026-07-09]

WatchKey bullets

Q2 clinical and reimbursement acceleration

Summary

High-level snapshot

Recommendation

Model confidence

high

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $15 (p=40%)

Target spread vs base: +7% / -25%

Scenario probabilities

Bull Target: $16 (p=45%)Base Target: $15 (p=40%)Bear Target: $12 (p=15%)

Commentary

News tone is positive because of the Tempus acquisition, strong Q2 clinical growth, and expanded Medicare coverage, but confidence is moderated by low coverage and missing social, options, short-interest, and post-print analyst data. The queue labels an August 11 earnings date, while the available company/SEC earnings release is dated August 4; no separate August 11 company release or transcript is included. The memo therefore remains a cautious, deal-supported monitoring view rather than a high-conviction standalone valuation call.

As of 2026-08-14 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

MRD adoption and further reimbursement expansion

Scenarios

Bull Target (Scenario probability)

$16 / p=45% prob

Base Target (Scenario probability)

$15 / p=40% prob

Bear Target (Scenario probability)

$12 / p=15% prob

Analysis 2026-08-14 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

72.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-04
Q2 clinical and reimbursement acceleration
Q2 revenue rose 30% year over year to $22.4 million, clinical revenue rose 442% to $2.6 million, and clinical test volume rose 199% to 10,384. Medicare coverage expanded NeXT Personal to four indications. [#SEC-8K-2026-08-04] [#PR-EARNINGS-2026-08-04]
Prob 85.00% • Move 5.00% • Priced-in 80.00%
EVENT2026-11-12
Tempus acquisition spread resolution
Tempus agreed to acquire Personalis for stated consideration of $16.25 per share, implying roughly 12.7% upside from the $14.42 anchor price, subject to transaction-closing conditions and Tempus-stock exposure. [#SEC-8K-2026-07-20]
Prob 75.00% • Move 12.70% • Priced-in 80.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

MRD adoption and further reimbursement expansion
2027-08-14
More than 1,400 physicians were ordering NeXT Personal, while management cited ongoing evidence generation to support reimbursement expansion into additional indications. Execution remains the key uncertainty. [#PR-EARNINGS-2026-08-04]
Prob 60% • Move 15% • Priced-in 55%

Risks

Clinical growth depends on reimbursement expansion, physician adoption, and continued evidence generation.
Insider Form 4 activity included open-market sales by senior officers; this is a sentiment and alignment risk, not evidence of operating deterioration. [#SEC-FORM4-2026-07-15] [#SEC-FORM4-2026-07-09]
Population-sequencing revenue declined 9% year over year in Q2. [#SEC-8K-2026-08-04]
Tempus transaction may be delayed, terminated, or affected by approval, shareholder, integration, or Tempus-share-price conditions. [#SEC-8K-2026-07-20]
The company reported a Q2 net loss of $31.7 million, leaving execution and cash-burn discipline important despite approximately $212.7 million of cash, cash equivalents, and short-term investments. [#PR-EARNINGS-2026-08-04]
The packet does not provide dependable post-print analyst revisions, options data, short interest, or a verified post-release market-reaction attribution.

Peers

Symbol	Summary
BCAX	Same-sector and similar-market-cap candidate, but not a direct MRD diagnostic comparable; comparison confidence is low.
MAZE	Same-sector and similar-market-cap clinical-stage biotech candidate, with limited comparability to Personalis's commercial precision-oncology diagnostics.
TRAX	Similar-market-cap life-sciences candidate, but the peer relationship is loose and not suitable for precise valuation benchmarking.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-14

Loading AI feed…

Symbol

Summary

BCAX

Same-sector and similar-market-cap candidate, but not a direct MRD diagnostic comparable; comparison confidence is low.

MAZE

Same-sector and similar-market-cap clinical-stage biotech candidate, with limited comparability to Personalis's commercial precision-oncology diagnostics.

TRAX

Similar-market-cap life-sciences candidate, but the peer relationship is loose and not suitable for precise valuation benchmarking.